Bipolar disorders treatment market analysis | Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• BIPOLAR DISORDERS TREATMENT MARKET ANALYSIS
• Bipolar Disorder Treatment Market, By Drug Class
  (Antipsychotics, Antidepressants, Mood
  Stabilizers, and Anti-anxiety Drugs and Others),
  By Distribution Channel (Hospital Pharmacies,
  Retail Pharmacies, and Online Pharmacies), and by
  Region (North America, Latin America, Europe,
  Asia Pacific, Middle East, and Africa) - Size,
  Share, Outlook, and Opportunity Analysis, 2019 -
  2027

3

• Bipolar disorder, also known as manic illness, is
  a brain disorder that affects the mood, energy
  level, and other activities. This disorder
  consists of various episodes, and major among
  these are manic and depression. There is a
  sudden change in mood of the patient and his/her
  ability to carry out daily tasks. There are four
  types of bipolar disorders bipolar I, bipolar
  II, cyclothymic, and other specified and
  non-specified bipolar and related disorders.
• The people suffering from bipolar disorder
  experience periods of unusually intense emotion,
  irregular sleep patterns and activity levels, and
  mood episodes. Bipolar disorder is diagnosed
  based on the patients symptoms, family history,
  and lifetime history. The healthcare provider
  generally conducts a mental health evaluation for
  the diagnosis of bipolar disorder.
• The global bipolar disorder treatment market size
  is estimated to be valued at US 7,288.3 million
  in 2019 and is expected to exhibit a CAGR of 5.2
  over the forecast period (2019-2027).

4

• Figure 1. Global Bipolar Disorder Treatment
  Market Value (US Mn), by Region, 2019

5

• Increasing product approvals and launches are
  expected to propel the market growth over the
  forecast period
• Key players are focusing on enhancing their
  product portfolio through increasing launches and
  approvals of new drugs for the treatment of
  bipolar disorder, which is expected to drive
  growth of the bipolar disorder treatment market
  over the forecast period. For instance, in May
  2019, Allergan plc and Gedeon Richter Plc.
  received the U.S. Food and Drug Administration
  (FDA) approval for its supplemental new drug
  application (sNDA) of VRAYLAR (cariprazine),
  anoral, once daily atypical antipsychotic drug
  for expanded use and treatment of depressive
  episodes associated with bipolar I disorder
  (bipolar depression) in adults.
• Moreover, in May 2016, Procera Health announced
  the launch of ProceraMood, a non-prescription
  drug, which offers mood stabilization, and
  supporting balance and calmness.

6
Figure 2. Global Bipolar Disorder Treatment
Market Share (), by Drug Class, 2019 and 2027

7
Increasing mergers, agreements, and
collaborations to develop treatment for bipolar
disorder is expected to drive the market growth
over the forecast period

• Market players are focused on adoption of
  inorganic growth strategies such as
  collaborations and partnerships to strengthen
  their position in the bipolar disorder treatment
  market. For instance, in November 2017, Sumitomo
  Dainippon Pharma Co., Ltd and Angelini S.p.A
  entered into a strategic partnership in order to
  distribute and commercialize Latuda (Lurasidone
  Hydrochloride), developed by Sumitomo Dainippon
  Pharma, in the European market (29 European
  countries and in Turkey). Under this agreement, a
  subsidiary company of Sumitomo Dainippon Pharma
  Group (Sunovion Pharmaceuticals Europe Ltd.)
  granted rights to Angelini for distribution and
  commercialization of LATUDA in European Market.
• However, side effects associated with drugs used
  in the treatment of bipolar disorder is expected
  to be a factor negatively affecting growth of the
  market up to certain extent, as patients hesitate
  to undergo medication therapy due to fear of the
  same. For instance, some of the medications
  including carbamazepine, Divalproex sodium, and
  Lithium used in the treatment of bipolar disorder
  have some side effects such as nausea, tremors,
  sexual problem, impaired memory, muscle weakness,
  decreased thyroid function, liver and kidney
  damage, skin reactions, and others.

8
Key Players

• Major players operating in the global bipolar
  disorder treatment market include Takeda
  Pharmaceutical Company Limited, Pfizer, Inc.,
  Allergan plc, Otsuka Holdings Co. Ltd., Johnson
  Johnson, Eli Lilly and Company, GlaxoSmithKline
  plc, AstraZeneca Plc, Novartis International AG,
  AbbVie Inc., H. Lundbeck A/S, Minerva
  Neurosciences, Sumitomo Dainippon Pharma Co.,
  Ltd., Intra-Cellular Therapies Inc., Gedeon
  Richter Plc., and Indivior PLC.

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/bipolar-disorders-treatment-market-
  2605

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

12
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/